Strategy

Setting the pace in radiopharmaceutical development

Read more

New opportunities for small molecules in cancer

Read more

Swiss companies weather the turmoil in 2022

Read more

Capturing the promise of p38 MAPK inhibition

Read more

Destiny Pharma advances strategy against bacteria

Read more

Adrenomed prepares global study in septic shock

Read more

Microbiome-based therapies as anti-cancer agents

Read more

Antibody-drug conjugates come to the fore

Read more

Antimicrobial Review: New research, new payment models

Read more

Cancer Research UK has new model

Read more